Approval of Osimertinib and Necitumumab Increases Lung Cancer Treatment Options

Last month, the Food and Drug Administration (FDA) approved two targeted therapies for patients with advanced non-small cell lung cancer (NSCLC).

The agency approved osimertinib (Tagrisso™) for patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation in their tumors after prior treatment with an EGFR-targeted therapy, and necitumumab (Portrazza™), in combination with standard chemotherapy drugs, for the initial treatment of patients with metastatic squamous NSCLC.

from Cancer via ola Kala on Inoreader http://ift.tt/1Vn7o3T
via IFTTT